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Epigenetic mechanisms
The  term  ‘epigenetic’  describes  a  group  of  heritable, 
distinct,  highly  interrelated  processes  that  control  the 
level of mRNA [1]. The main processes are DNA methy­
lation and covalent modifications to the amino termini of 
histones, principally methylation, acetylation, ubiquitina­
tion and phosphorylation. Epigenetic control of mRNA 
levels can also be conferred through the action of small 
interfering  mRNAs.  Epigenetic  regulation  by  DNA 
methylation is primarily mediated by the addition of CH3 
to carbon 5 of cytosines in CpG dinucleotide pairs that 
cluster in the 5’ regulatory regions of genes, known as 
CpG islands [1], although other modifications have been 
described.  In  general,  methylated  DNA  sequences  are 
associated  with  gene  silencing,  whereas  unmethylated 
CpG islands are associated with transcriptional activity. 
However,  methylation  of  individual  CpG  dinucleotides 
allows graded control of transcription through differ  en­
tial changes in the binding of transcription factors and 
other proteins. Thus, methylation of a CpG that influ­
ences a response element for an inhibitory transcription 
factor could enhance the level of transcription.
The genome is rapidly demethylated in early embryos, 
with the exception of parentally imprinted genes. This is 
followed  by  gene­specific  patterns  of  DNA  silencing, 
which are fundamental to cell differentiation and which 
are  induced  de  novo  by  the  activities  of  DNA  methyl­
transferases (Dnmts) 3a and 3b, possibly in association 
with Polycomb proteins. Patterns of methylated cytosines 
are  maintained  during  DNA  replication  by  Dnmt­1, 
which uses the hemimethylated DNA as a template.
It is generally thought that patterns of DNA methyla­
tion  induced  during  early  development  are  stable 
through  out the life course. However, a recent study [2] of 
the level of methylation of individual CpG dinucleotides 
in  the  serotonin  transporter  gene  in  buccal  cells  from 
monozygotic and dizygotic twins collected at 5 and 10 
years has shown that in 32% of the children studied, there 
was a 5% difference in methylation, and 14% of children 
had a difference of at least 10% over 5 years (overall range 
for  the  whole  group  ­41%  to  +23%).  One  possible 
explanation for such variation could lie in the proposed 
dynamic  nature  of  DNA  methylation.  Szyf  [3]  has 
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increased disease risk. Identification of such processes 
suggests the potential for developing biomarkers of 
disease risk and for interventions to prevent or reverse 
the adverse effects of a poor early life environment. 
At present, knowledge in this area is limited to 
proof-of-principle studies in animal models and 
some initial studies in humans. Before such findings 
can be translated into reliable biomarkers and safe, 
effective interventions, several fundamental questions 
need to be answered. In order to achieve this, new 
technologies will be needed to support large cohort 
studies. Despite the early stage of knowledge in this 
field and the intellectual, technological and financial 
challenges, epigenetic research has substantial 
potential for public health benefits.
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stable modification, the level at any one time represents 
the  equilibrium  between  the  activities  of  Dnmts  and 
demethylases such that a shift in the activities of these 
enzymes could alter the level of methylation even in non­
dividing  cells.  If  correct,  this  could  have  important 
implications  for  understanding  the  epigenetic  effects 
described below.
Epigenetic control of transcription by histone modifi­
cations might be regarded as more dynamic than control 
by DNA methylation. However, the two are closely linked 
through the binding of specific proteins, such as methyl 
CpG  binding  proteins  and  methyl  domain  binding 
proteins, to methylated DNA sequences, which, in turn, 
recruit histone modifying enzymes [1], and through the 
recruitment of Dnmts to DNA by histone deacetylase­1 
and  the  Polycomb  protein  EZH2  [4,5].  In  general, 
acetylation of histones is associated with transcriptionally 
active euchromatin, whereas removal of acetyl groups by 
histone deacetylases and methylation of specific amino 
acid  residues  by  histone  methyl  transferases  induces 
compact, transcriptionally silenced heterochromatin.
Epigenetic processes can be modified by environmental 
signals and therefore provide a mechanism by which the 
expression  level  of  a  gene  can  be  adjusted  in  order  to 
facilitate cellular response. There is emerging evidence that 
modifications in epigenetic processes may be an important 
causal factor in disease risk throughout the life course.
The early life environment and future disease risk
Constraint  in  the  early  life  environment,  such  as  poor 
nutrition  and  endocrine  factors,  induces  a  life­long 
increase  in  the  risk  of  non­communicable  diseases, 
includ  ing  cardio­metabolic  disease,  affective  disorders, 
osteoporosis  and  cancer  [6].  This  involves  an  induced 
change  in  the  phenotype  of  the  offspring  by  environ­
mental  cues  that  act  through  developmental  plasticity. 
The  induced  phenotype  change  may  represent  adapta­
tions that predict the future environment but that result 
in disease if the prediction is incorrect [7]. Such pheno­
typic  changes  involve  altered  epigenetic  regulation  of 
specific genes.
So far, the majority of reports in this area have been 
proof­of­principle  studies  in  experimental  models, 
although  there  have  been  some  recent  reports  on  the 
effect of early life environment on epigenetic processes in 
humans. Uterine artery ligation in rats induced decreased 
methylation and increased expression of the p53 promo­
ter in the kidneys of the offspring, which was associa  ted 
with impaired development of kidney structure [8]. Poor 
maternal nursing in rats was associated with increased 
methylation of a CpG in the glucocorticoid receptor (GR) 
gene  in  the  hippocampus  in  the  offspring,  which 
impaired  binding  of  nerve  growth  factor  1­A  to  its 
recep  tor and was associated with poor stress response in 
adulthood  [9].  Altered  methylation  was  reversed  by 
cross­fostering the offspring after birth or by infusion of 
a histone deacetylase inhibitor [9]. Hypermethylation of a 
CpG  in  a  comparable  region  of  the  GR  promoter  in 
human brain was also found in individuals with a history 
of childhood abuse who subsequently committed suicide 
[10]. These studies [8­10] have important implications for 
understanding how the early life environment can affect 
future  patterns  of  behavior  and  for  susceptibility  to 
mental illness.
The  quality  of  nutrition  during  development  is  an 
important causal factor in future disease risk in humans, 
in particular cardiovascular disease and metabolic syn­
drome [6]. In Agouti viable yellow (Avy) mice, increased 
intake of methyl donors and folic acid induced a graded 
switch in coat color by inducing increased methylation of 
a retrotransposon containing a cryptic promoter located 
proximal to the Agouti gene [11]. In rats, neonatal over­
feeding due to small litter size induced hypermethylation 
of the hypothalamic insulin receptor and proopio  melano­
cortin  promoters  [12,13].  Feeding  a  protein­restricted 
(PR) diet to pregnant rats induced hypomethylation of 
and increased mRNA expression from the promoters of 
the GR and peroxisome proliferator­activated receptor α 
(PPARα) genes in the liver of the offspring [14]. Hypo­
methylation of the GR promoter was accompanied by an 
increased  level  of  the  histone  modifications  normally 
associated with active transcription, and with decreased 
expression  of  Dnmt1  and  lower  levels  of  binding  of 
Dnmt1  to  the  GR  promoter  [15].  This  suggested  that 
induc  tion of hypomethylation of GR may involve im  paired 
capacity for maintaining methylation patterns during cell 
replication. Analysis of individual CpGs in the liver PPARα 
promoter showed that four CpGs were hypomethylated in 
the offspring of dams fed a PR diet; two of these CpGs 
predicted the level of transcription [16].
Supplementation of the maternal PR diet with folic acid 
prevented the induction of an altered phenotype and of 
hypomethylation of the GR and PPARα promoters [14]. 
However,  within  the  PPARα  promoter,  two  CpGs  that 
were unaffected by the PR diet alone were hyper  methy­
lated in the offspring of dams fed the folic acid supple­
mented diet [16]. Thus, although folic acid supplemen­
tation  seemed  to  prevent  the  induction  of  an  altered 
phenotype and epigenotype, this intervention may have 
induced a vulnerability in the regulation of this gene, and 
potentially of others. This is supported by the finding that 
the maternal PR diet induced a persistent change in 311 
genes in the liver of the adult offspring, whereas the folic 
acid supplemented PR diet altered the mRNA expression 
of 191 [17]. However, only 16 genes were altered in both 
groups  of  offspring  [17].  Furthermore,  folic  acid 
supplementation of the offspring of rats fed a control or 
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period  induced  dyslipidemia  and  hepatosteatosis  (fatty 
liver) irrespective of maternal diet, and this was accom­
panied by hypermethylation of the liver PPARα promoter 
and hypermethylation of the insulin receptor in adipose 
tissue [18]. Despite the deleterious effects of folic acid 
supplementation,  these  findings  show  that  epigenetic 
plasticity extends beyond the period of early development 
and that the epigenetic regulation of specific genes can be 
modified by dietary interventions in free living offspring.
Two recent studies [19­21] have reported the effect of 
prenatal  under­nutrition  on  promoter  methylation  in 
humans. Individuals who were in utero during the 1944­
45 famine in the Netherlands show an increased risk of 
cardio­metabolic  disease  compared  with  unexposed 
individuals [19]. The precise pattern of disease is contin­
gent on the timing during development of expo  sure to 
famine.  Adults  who  were  exposed  to  famine  in  utero 
showed  altered  DNA  methylation  in  the  promoters  of 
several  imprinted  and  non­imprinted  genes  in  white 
blood cells [20,21]. However, the difference between ex­
posed and unexposed individuals was small (around 5%) 
compared  with  that  in  the  GR  promoter  of  childhood 
abuse victims [9] (about 30%), which makes the biological 
significance  of  findings  of  these  studies  difficult  to 
interpret.
Translation of knowledge about epigenetic 
processes into public health policy
The  identification  of  a  role  for  epigenetic  processes  in 
differential  risk  of  non­communicable  diseases  is  an 
impor  tant  step  towards  interventions  to  prevent  or 
reverse risk of these conditions. Given that cardio­meta­
bolic disease and cancer develop subclinically throughout 
the life course, such knowledge could also be applied to 
the  development  of  epigenetic  markers  of  disease  risk 
before the clinical phase of the condition or to monitor 
the efficacy of an intervention.
In order to translate knowledge about epigenetics for 
use in a healthcare or public health context, several key 
issues  need  to  be  addressed.  Which  epigenetic  marks 
should  be  targeted  and  in  which  genes?  What  is  the 
variation  in  these  epigenetic  marks  in  the  general 
population and how does this equate to disease risk? Are 
there tissues in which epigenetic marks can act as a proxy 
for  those  in  less  accessible,  but  clinically  important, 
tissues? The following additional questions also need to 
be considered. Given that the same treatment can induce 
opposite effects in different genes within the same tissue, 
how  can  interventions  be  targeted  to  produce  benefit 
without  also  inducing  vulnerability  in  gene  regulation, 
which  could  increase  disease  risk?  How  plastic  is  the 
epigenome during the life course? When are epigenetic 
biomarkers likely to be of use and when are interventions 
likely to be most effective? How do epigenetic and genetic 
variation interact?
Answering  these  questions  is  a  major  challenge,  not 
least in terms of financial investment. Furthermore, new 
technologies, such as methods for rapid sequencing of 
differentially methylated regions of the genome, need to 
be developed before large­scale epidemiological studies 
can be conducted.
Conclusions
At present, because of the relative novelty of the field, the 
challenges that need to be overcome in order to develop 
useful biomarkers and safe and effective interventions are 
substantial.  Nevertheless,  the  potential  benefits  from 
research in this area are likely to be considerable.
Abbreviations
Dnmt, DNA methyltransferase; GR, glucocorticoid receptor; PPARα, peroxisome 
proliferator-activated receptor α; PR, protein-restricted.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
GCB and KAL contributed equally to the planning and writing of this 
manuscript. Both authors read and approved the final manuscript.
Acknowledgements
Research in the authors’ laboratory is funded by the British Heart Foundation 
and the Biotechnology and Biological Sciences Research Council.
Author details
1Institute of Human Nutrition, University of Southampton School of Medicine, 
Institute of Developmental Sciences Building (MP887), Southampton General 
Hospital, Tremona Road, Southampton, SO16 6YD, UK. 2Development and Cell 
Biology, University of Southampton School of Biological Sciences, Institute of 
Developmental Sciences Building (MP887), Southampton General Hospital, 
Tremona Road, Southampton, SO16 6YD, UK.
Published: 5 November 2010
References
1.  Goldberg AD, Allis CD, Bernstein E: Epigenetics: a landscape takes shape. 
Cell 2007, 128:635-638.
2.  Wong CCY, Caspi A, Williams B, Craig IW, Houts, R, Ambler A, Moffitt TE, Mill J: 
A longitudinal study of epigenetic variation in twins. Epigenetics 2010, 
5:516-526.
3.  Szyf M: The dynamic epigenome and its implications in toxicology. Toxicol 
Sci 2007, 100:7-23.
4.  Rountree MR, Bachman KE, Baylin SB: DNMT1 binds HDAC2 and a new 
co-repressor, DMAP1, to form a complex at replication foci. Nat Genet 2000, 
25:269-277.
5.  Viré E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van 
Eynde A, Bernard D, Vanderwinden JM, Bollen M, Esteller M, Di Croce L, de 
Launoit Y, Fuks F: The Polycomb group protein EZH2 directly controls DNA 
methylation. Nature 2006, 439:871-874.
6.  Gluckman PD, Hanson MA, Cooper C, Thornburg KL: Effect of in utero and 
early-life conditions on adult health and disease. N Engl J Med 2008, 
359:61-73.
7.  Gluckman PD, Hanson MA: Living with the past: evolution, development, 
and patterns of disease. Science 2004, 305:1733-1736.
8.  Pham TD, MacLennan NK, Chiu CT, Laksana GS, Hsu JL, Lane RH: 
Uteroplacental insufficiency increases apoptosis and alters p53 gene 
methylation in the full-term IUGR rat kidney. Am J Physiol Regul Integr Comp 
Physiol 2003, 285:R962-R970.
9.  Weaver IC, Cervoni N, Champagne FA, D’Alessio AC, Sharma S, Seckl JR, 
Burdge and Lillycrop Genome Medicine 2010, 2:80 
http://genomemedicine.com/content/2/11/80
Page 3 of 4Dymov S, Szyf M, Meaney MJ: Epigenetic programming by maternal 
behavior. Nat Neurosci 2004, 7:847-854.
10.  McGowan PO, Sasaki A, Huang TC, Unterberger A, Suderman M, Ernst C, 
Meaney MJ, Turecki G, Szyf M: Promoter-wide hypermethylation of the 
ribosomal RNA gene promoter in the suicide brain. PLoS ONE 2008, 
3:e2085.
11.  Waterland RA, Jirtle RL: Transposable elements: targets for early nutritional 
effects on epigenetic gene regulation. Mol Cell Biol 2003, 23:5293-5300.
12.  Plagemann A, Harder T, Brunn M, Harder A, Roepke K, Wittrock-Staar M, Ziska 
T, Schellong K, Rodekamp E, Melchior K, Dudenhausen JW: Hypothalamic 
proopiomelanocortin promoter methylation becomes altered by early 
overfeeding: an epigenetic model of obesity and the metabolic 
syndrome. J Physiol 2009, 587:4963-4976.
13.  Plagemann A, Roepke K, Harder T, Brunn M, Harder A, Wittrock-Staar M, Ziska 
T, Schellong K, Rodekamp E, Melchior K, Dudenhausen JW: Epigenetic 
malprogramming of the insulin receptor promoter due to developmental 
overfeeding. J Perinat Med 2010, 38:393-400.
14.  Lillycrop KA, Phillips ES, Jackson AA, Hanson MA, Burdge GC: Dietary protein 
restriction of pregnant rats induces and folic acid supplementation 
prevents epigenetic modification of hepatic gene expression in the 
offspring. J Nutr 2005, 135:1382-1386.
15.  Lillycrop KA, Slater-Jefferies JL, Hanson MA, Godfrey KM, Jackson AA, Burdge 
GC: Induction of altered epigenetic regulation of the hepatic 
glucocorticoid receptor in the offspring of rats fed a protein-restricted 
diet during pregnancy suggests that reduced DNA methyltransferase-1 
expression is involved in impaired DNA methylation and changes in 
histone modifications. Br J Nutr 2007, 97:1064-1073.
16.  Lillycrop KA, Phillips ES, Torrens C, Hanson MA, Jackson AA, Burdge GC: 
Feeding pregnant rats a protein-restricted diet persistently alters the 
methylation of specific cytosines in the hepatic PPARalpha promoter of 
the offspring. Br J Nutr 2008, 100:278-282.
17.  Lillycrop KA, Rodford J, Garratt ES, Slater-Jefferies JL, Godfrey KM, Gluckman 
PD, Hanson MA, Burdge GC: Maternal protein restriction with or without 
folic acid supplementation during pregnancy alters the hepatic 
transcriptome in adult male rats. Br J Nutr 2010, 103:1711-1719.
18.  Burdge GC, Lillycrop KA, Phillips ES, Slater-Jefferies JL, Jackson AA, Hanson 
MA: Folic acid supplementation during the juvenile-pubertal period in rats 
modifies the phenotype and epigenotype induced by prenatal nutrition. 
J Nutr 2009, 139:1054-1060.
19.  Roseboom T, de RS, Painter R: The Dutch famine and its long-term 
consequences for adult health. Early Hum Dev 2006, 82:485-491.
20.  Heijmans BT, Tobi EW, Stein AD, Putter H, Blauw GJ, Susser ES, Slagboom PE, 
Lumey LH: Persistent epigenetic differences associated with prenatal 
exposure to famine in humans. Proc Natl Acad Sci USA 2008, 
105:17046-17049.
21.  Tobi EW, Lumey LH, Talens RP, Kremer D, Putter H, Stein AD, Slagboom PE, 
Heijmans BT: DNA methylation differences after exposure to prenatal 
famine are common and timing- and sex-specific. Hum Mol Genet 2009, 
18:4046-4053.
doi:10.1186/gm201
Cite this article as: Burdge GC, Lillycrop KA: Bridging the gap between 
epigenetics research and nutritional public health interventions. Genome 
Medicine 2010, 2:80.
Burdge and Lillycrop Genome Medicine 2010, 2:80 
http://genomemedicine.com/content/2/11/80
Page 4 of 4